Successful Treatment of Urinary Tract Infection in Kidney Transplant Recipients Caused by Multiresistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lactamase (NDM-1) With Strains Genotyping

Transplant Proc. 2016 Jun;48(5):1576-9. doi: 10.1016/j.transproceed.2016.01.060.

Abstract

Background: Klebsiella pneumoniae New Delhi metallo-beta-lactamase-1 (NDM-1) strains have recently become a new threat in kidney transplant recipients due to the strains' resistance to almost all antibiotics, including carbapenems.

Methods: We present a case series of 3 patients with urinary tract infections (UTIs) caused by multiresistant K pneumoniae NDM-1 strains who were treated with the same protocol. Genotyping sequencing with pulsed-field gel electrophoresis was performed in all cases.

Results: All patients were male and had undergone kidney transplantation 4, 7, and 8 months, respectively, before the admission. Combined antibiotic therapy consisting of imipenem/cilastatin in maximal doses, gentamicin and/or colistin for 21 to 27 days, followed by oral fosfomycin, was used in all cases. There were no further UTI episodes in 2 patients at the 12-month visit. Three months after initial treatment, the third patient presented with leukocyturia with no clinical symptoms and a urine culture positive for K pneumonia NDM-1 strain. Interestingly, the strain was susceptible to trimethoprim/sulfamethoxazole despite resistance in previous urine culture samples. The patient was successfully treated with trimethoprim/sulfamethoxazole 2 × 960 mg/d for 3 weeks followed by 480 mg/d and 3 doses of fosfomycin. Genotyping sequencing revealed identical DNA restriction fragments in bacterial strains from 2 patients. In the third case, although a difference in 2 restriction fragments was observed, the strain was considered related to the others.

Conclusions: In cases of UTI caused by K pneumoniae NDM-1 strains, prolong combined treatment followed by oral fosfomycin prophylaxis can be successful. Strain genotyping should be performed to optimize further treatment protocols in such cases.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Cilastatin / therapeutic use
  • Cilastatin, Imipenem Drug Combination
  • Colistin / therapeutic use
  • Drug Combinations
  • Drug Resistance, Microbial
  • Electrophoresis, Gel, Pulsed-Field
  • Fosfomycin / therapeutic use
  • Genotype
  • Gentamicins / therapeutic use
  • Humans
  • Imipenem / therapeutic use
  • Kidney Transplantation*
  • Klebsiella Infections / drug therapy*
  • Klebsiella Infections / genetics
  • Klebsiella pneumoniae / genetics
  • Male
  • Microbial Sensitivity Tests
  • Transplant Recipients
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Urinary Tract Infections / drug therapy*
  • Urinary Tract Infections / microbiology
  • beta-Lactamases / biosynthesis

Substances

  • Anti-Bacterial Agents
  • Drug Combinations
  • Gentamicins
  • Cilastatin
  • Fosfomycin
  • Imipenem
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Cilastatin, Imipenem Drug Combination
  • beta-Lactamases
  • beta-lactamase NDM-1
  • Colistin